inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: A clinicopathologic, cytogenetic, and molecular study of five cases

Mihai Merzianu, L. Jeffrey Medeiros, Jorge Cortes, Cameron Yin, Pei Lin, Dan Jones, Armand Glassman, Hagop Kantarjian, Yang Huh

Research output: Contribution to journalArticle

Abstract

Blast phase (BP) in chronic myelogenous leukemia (CML) frequently is accompanied by cytogenetic abnormalities in addition to t(9;22)(q34;q11.2). We describe 5 patients with CML in blast phase (CML-BP) in which t(9;22) and inv(16)(p13q22) were identified by conventional cytogenetics, with confirmation of BCR/ABL and CBFβ/MYH11 by fluorescence in situ hybridization. The morphologic findings at the time of BP resembled de novo acute myeloid leukemia (AML) carrying inv(16)(p13q22), with abnormal eosinophils in the bone marrow and monocytosis in the peripheral blood in all cases. In 1 patient, inv(16)(p13q22) and abnormal eosinophils were detected in the bone marrow 2 months before CML-BP. The clinical course of these patients was similar to patients with CML-BP without evidence of inv(16)(p13q22). These cases illustrate that inv(16)(p13q22) is a form of cytogenetic evolution that rarely occurs in patients with CML at the time of BP. In this setting, unlike de novo AML, inv(16)(p13q22) in CML-BP is not associated with a favorable prognosis.

Original languageEnglish (US)
Pages (from-to)807-814
Number of pages8
JournalAmerican Journal of Clinical Pathology
Volume124
Issue number5
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Blast Crisis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Eosinophils
Acute Myeloid Leukemia
Bone Marrow
Fluorescence In Situ Hybridization
Chromosome Aberrations

Keywords

  • Blast phase
  • Chronic myelogenous leukemia
  • Clonal evolution
  • inv(16)
  • t(9;22)

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

inv(16)(p13q22) in chronic myelogenous leukemia in blast phase : A clinicopathologic, cytogenetic, and molecular study of five cases. / Merzianu, Mihai; Medeiros, L. Jeffrey; Cortes, Jorge; Yin, Cameron; Lin, Pei; Jones, Dan; Glassman, Armand; Kantarjian, Hagop; Huh, Yang.

In: American Journal of Clinical Pathology, Vol. 124, No. 5, 11.2005, p. 807-814.

Research output: Contribution to journalArticle

Merzianu, Mihai ; Medeiros, L. Jeffrey ; Cortes, Jorge ; Yin, Cameron ; Lin, Pei ; Jones, Dan ; Glassman, Armand ; Kantarjian, Hagop ; Huh, Yang. / inv(16)(p13q22) in chronic myelogenous leukemia in blast phase : A clinicopathologic, cytogenetic, and molecular study of five cases. In: American Journal of Clinical Pathology. 2005 ; Vol. 124, No. 5. pp. 807-814.
@article{c08d2c3f09e54f9a8ccb679cdaf0b378,
title = "inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: A clinicopathologic, cytogenetic, and molecular study of five cases",
abstract = "Blast phase (BP) in chronic myelogenous leukemia (CML) frequently is accompanied by cytogenetic abnormalities in addition to t(9;22)(q34;q11.2). We describe 5 patients with CML in blast phase (CML-BP) in which t(9;22) and inv(16)(p13q22) were identified by conventional cytogenetics, with confirmation of BCR/ABL and CBFβ/MYH11 by fluorescence in situ hybridization. The morphologic findings at the time of BP resembled de novo acute myeloid leukemia (AML) carrying inv(16)(p13q22), with abnormal eosinophils in the bone marrow and monocytosis in the peripheral blood in all cases. In 1 patient, inv(16)(p13q22) and abnormal eosinophils were detected in the bone marrow 2 months before CML-BP. The clinical course of these patients was similar to patients with CML-BP without evidence of inv(16)(p13q22). These cases illustrate that inv(16)(p13q22) is a form of cytogenetic evolution that rarely occurs in patients with CML at the time of BP. In this setting, unlike de novo AML, inv(16)(p13q22) in CML-BP is not associated with a favorable prognosis.",
keywords = "Blast phase, Chronic myelogenous leukemia, Clonal evolution, inv(16), t(9;22)",
author = "Mihai Merzianu and Medeiros, {L. Jeffrey} and Jorge Cortes and Cameron Yin and Pei Lin and Dan Jones and Armand Glassman and Hagop Kantarjian and Yang Huh",
year = "2005",
month = "11",
doi = "10.1309/3HFE16DKMB1DBFMN",
language = "English (US)",
volume = "124",
pages = "807--814",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "5",

}

TY - JOUR

T1 - inv(16)(p13q22) in chronic myelogenous leukemia in blast phase

T2 - A clinicopathologic, cytogenetic, and molecular study of five cases

AU - Merzianu, Mihai

AU - Medeiros, L. Jeffrey

AU - Cortes, Jorge

AU - Yin, Cameron

AU - Lin, Pei

AU - Jones, Dan

AU - Glassman, Armand

AU - Kantarjian, Hagop

AU - Huh, Yang

PY - 2005/11

Y1 - 2005/11

N2 - Blast phase (BP) in chronic myelogenous leukemia (CML) frequently is accompanied by cytogenetic abnormalities in addition to t(9;22)(q34;q11.2). We describe 5 patients with CML in blast phase (CML-BP) in which t(9;22) and inv(16)(p13q22) were identified by conventional cytogenetics, with confirmation of BCR/ABL and CBFβ/MYH11 by fluorescence in situ hybridization. The morphologic findings at the time of BP resembled de novo acute myeloid leukemia (AML) carrying inv(16)(p13q22), with abnormal eosinophils in the bone marrow and monocytosis in the peripheral blood in all cases. In 1 patient, inv(16)(p13q22) and abnormal eosinophils were detected in the bone marrow 2 months before CML-BP. The clinical course of these patients was similar to patients with CML-BP without evidence of inv(16)(p13q22). These cases illustrate that inv(16)(p13q22) is a form of cytogenetic evolution that rarely occurs in patients with CML at the time of BP. In this setting, unlike de novo AML, inv(16)(p13q22) in CML-BP is not associated with a favorable prognosis.

AB - Blast phase (BP) in chronic myelogenous leukemia (CML) frequently is accompanied by cytogenetic abnormalities in addition to t(9;22)(q34;q11.2). We describe 5 patients with CML in blast phase (CML-BP) in which t(9;22) and inv(16)(p13q22) were identified by conventional cytogenetics, with confirmation of BCR/ABL and CBFβ/MYH11 by fluorescence in situ hybridization. The morphologic findings at the time of BP resembled de novo acute myeloid leukemia (AML) carrying inv(16)(p13q22), with abnormal eosinophils in the bone marrow and monocytosis in the peripheral blood in all cases. In 1 patient, inv(16)(p13q22) and abnormal eosinophils were detected in the bone marrow 2 months before CML-BP. The clinical course of these patients was similar to patients with CML-BP without evidence of inv(16)(p13q22). These cases illustrate that inv(16)(p13q22) is a form of cytogenetic evolution that rarely occurs in patients with CML at the time of BP. In this setting, unlike de novo AML, inv(16)(p13q22) in CML-BP is not associated with a favorable prognosis.

KW - Blast phase

KW - Chronic myelogenous leukemia

KW - Clonal evolution

KW - inv(16)

KW - t(9;22)

UR - http://www.scopus.com/inward/record.url?scp=27444436578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27444436578&partnerID=8YFLogxK

U2 - 10.1309/3HFE16DKMB1DBFMN

DO - 10.1309/3HFE16DKMB1DBFMN

M3 - Article

C2 - 16203287

AN - SCOPUS:27444436578

VL - 124

SP - 807

EP - 814

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 5

ER -